SCHEDULE: Glazer Capital Discloses 5.4% Stake in Day One Bio

Glazer Capital, LLC and Paul J. Glazer have reported a 5.4% beneficial ownership stake in Day One Biopharmaceuticals, Inc.

Summary

• Glazer Capital, LLC and Paul J. Glazer collectively reported beneficial ownership of 5,615,390 shares of Common Stock in DAY ONE BIOPHARMACEUTICALS, INC.
• This ownership represents 5.4% of the company's outstanding Common Stock.
• The reporting persons, Glazer Capital, LLC (an investment adviser) and Paul J. Glazer (its Managing Member), share both voting and dispositive power over all 5,615,390 shares.
• The shares are held by certain funds and managed accounts for which Glazer Capital serves as investment manager, collectively referred to as the Glazer Funds.
• Glazer Capital Enhanced Master Fund, Ltd., a Glazer Fund, has the right to receive or direct the proceeds from the sale of more than 5% of the outstanding Common Stock.
• The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by an institutional investor often indicates a belief in the company's long-term value or potential, without implying an activist stance.

Positives

• A significant institutional investor, Glazer Capital, has taken a 5.4% stake, potentially signaling confidence in Day One Biopharmaceuticals, Inc.'s future prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance from Day One Biopharmaceuticals, Inc. It is a disclosure of beneficial ownership by an external investment entity.

Management Comments

• Paul J. Glazer, Managing Member of Glazer Capital, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that the disclosure of a new significant stake by an institutional investor like Glazer Capital in a biopharmaceutical company can often be interpreted by the market as a vote of confidence in the company's pipeline, strategic direction, or valuation. Such filings are common as institutional investors cross reporting thresholds.

Stakeholder Impact

• Shareholders may view the entry of a new significant institutional investor as a positive indicator of the company's value and future prospects, potentially leading to increased investor confidence.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal. However, without additional financial or operational details from Day One Biopharmaceuticals, Inc., a definitive 'buy' or 'sell' recommendation cannot be made solely based on this ownership disclosure. A 'hold' recommendation is appropriate as it suggests monitoring the company's performance and future disclosures in light of this new institutional interest.

Keywords

Day One Biopharmaceuticals, Glazer Capital, Paul J. Glazer, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Management